Correspondingly, ARHGAP21 expression was increased in total bone marrow samples from de novo AML patients compared to MDS patients classified according to WHO classification [RS-SLD/RS-MLD/del(5q)/SLD/MLD (p = 0.0036) and EB-1/EB-2 (p = 0.0093)] (Supplementary Figure 2B). This evidence concerns the gene ARHGAP21 and myelodysplastic syndrome.